1. Phylogeny  
   LIM domain kinase 2 (LIMK2) belongs to the LIM kinase family, which comprises two closely related members, LIMK1 and LIMK2, and is evolutionarily conserved among vertebrates as well as in many lower eukaryotes. Orthologs of LIMK2 can be identified across a broad range of species, indicating its origin early in the evolution of eukaryotic serine/threonine kinases (brion2021limkinasesin pages 1-2, lateef2024limkinasesin pages 2-4). Within the kinome, LIMK2 is grouped with other dual-specificity kinases that share a unique LIM domain architecture; these LIM domains are characterized by a double zinc finger motif that is conserved among the family members and serve as modules for protein–protein interactions. The evolutionary relationship between LIMK2 and its paralog LIMK1 reveals approximately 50% overall sequence identity with increased conservation within the catalytic (kinase) domains (approximately 70% identity) (manetti2012limkinasesare pages 1-3, villalonga2023limkinaseslimk1 pages 1-2). This evolutionary lineage places LIMK2 in a group of kinases that are not only crucial for the regulation of actin cytoskeleton dynamics but also serve as key downstream effectors in Rho family GTPase signaling cascades (goyal2005dualfunctionof pages 24-28).
2. Reaction Catalyzed  
   LIMK2 catalyzes the transfer of a phosphate group from ATP to target proteins, primarily phosphorylating serine/threonine residues on substrate proteins such as cofilin. The chemical reaction it mediates can be summarized as follows: ATP + [protein]‐(L‐serine/threonine) → ADP + [protein]‐(L‐serine/threonine)‐phosphate + H⁺ (brion2021limkinasesin pages 2-4, chatterjee2022structuralaspectsof pages 1-3). This catalytic activity is central to its role in modulating the activity of proteins that control actin filament dynamics and thus impacts various cellular behaviors including motility and mitotic processes.
3. Cofactor Requirements  
   The kinase activity of LIMK2 is dependent upon the presence of divalent metal ions that act as essential cofactors for the binding and proper orientation of ATP within the catalytic cleft. In particular, Mg²⁺ is required as a cofactor to facilitate the transfer of the phosphate group from ATP to the substrate protein (chatterjee2022structuralaspectsof pages 6-8). This cofactor requirement is characteristic of many protein kinases and is critical for achieving the active conformation of the enzyme.
4. Substrate Specificity  
   LIMK2 demonstrates substrate specificity predominantly for actin‐regulating proteins. Its best‐characterized substrate is cofilin, an actin‐depolymerizing factor, which undergoes phosphorylation at serine 3, thereby leading to its inactivation and resulting in stabilization of actin filaments (brion2021limkinasesin pages 2-4, mashiachfarkash2012computerbasedidentificationof pages 2-4). In addition to cofilin, LIMK2 has been shown in vitro to phosphorylate myelin basic protein (MBP) and histone proteins, although these substrates are primarily used to demonstrate kinase activity under experimental conditions (brion2021limkinasesin pages 2-4). Furthermore, LIMK2 is involved in the phosphorylation of TPPP, a protein implicated in microtubule polymerization, which links its activity to astral microtubule organization and mitotic spindle orientation (brion2021limkinasesin pages 2-4). The substrate consensus motif tends to favor serine/threonine residues flanked by sequences that allow docking via the non-catalytic LIM and PDZ domains, although the precise amino acid consensus determined by high-throughput assays remains less clearly defined than for some other serine/threonine kinases (jiang2023pdzandlim pages 14-16).
5. Structure  
   LIMK2 displays a modular structure that is central to its function and regulation. Its N-terminal region comprises two LIM domains, each of which forms a zinc finger motif that coordinates zinc ions through conserved cysteine and histidine residues; these domains mediate protein–protein interactions and can exert autoinhibitory influence over the kinase activity (manetti2012limkinasesare pages 1-3, villalonga2023limkinaseslimk1 pages 2-6). Adjacent to the LIM domains, LIMK2 harbors a PDZ domain, which also facilitates specific interactions with target proteins and contributes to subcellular localization dynamics by engaging nuclear export signals (villalonga2023limkinaseslimk1 pages 2-6). This is followed by a serine/proline-rich region, which may function as a flexible linker that permits communication between the regulatory domains and the catalytic domain. The C-terminal kinase domain is responsible for its catalytic function and exhibits the classic bilobal fold characteristic of protein kinases. Key catalytic features include the activation loop, which contains the critical threonine residue (Thr505 in LIMK2) whose phosphorylation is necessary for full enzymatic activity; other important structural motifs include the glycine-rich loop responsible for ATP binding and the C-helix that participates in forming the active site (chatterjee2022structuralaspectsof pages 4-6, manetti2012limkinasesare pages 11-14). Furthermore, unique features such as a noncanonical DLNSHN motif in the catalytic subdomain provide LIMK2 with the ability to phosphorylate both serine/threonine and, in some contexts, tyrosine residues, underscoring its classification as a dual-specificity kinase (villalonga2023limkinaseslimk1 pages 9-10, yin2015bisarylureaderivatives pages 1-3).
6. Regulation  
   LIMK2 is subject to complex regulation via post-translational modifications and interactions with upstream signaling molecules. Its activation is primarily achieved through phosphorylation by kinases activated downstream of small Rho GTPases. For instance, Rho-associated kinases (ROCK1/2) and p21-activated kinases (PAKs) phosphorylate LIMK2 at Thr505 within its activation loop, which shifts the enzyme into an active conformation (goyal2005dualfunctionof pages 24-28, chatterjee2022structuralaspectsof pages 10-11). Aurora A kinase is also an upstream regulator that phosphorylates LIMK2 at multiple residues, including Ser283 and Thr494, influencing its subcellular localization, stability, and catalytic activity; this forms a positive feedback loop with Aurora A, particularly in cancer cells (johnson2012limk2isa pages 1-2, villalonga2023limkinaseslimk1 pages 13-15). In addition to these kinases, protein kinase C (PKC) has been implicated in regulating LIMK2 via phosphorylation of residues that modulate its nuclear import/export dynamics (goyal2005dualfunctionof pages 118-121, manetti2012limkinasesare pages 16-18). Autoinhibitory interactions mediated by its own LIM and PDZ domains may also constrain the basal activity of LIMK2 until proper upstream signals relieve this inhibition (villalonga2023limkinaseslimk1 pages 2-6). The net outcome of these modifications is the fine-tuning of LIMK2 activity to ensure precise control over actin dynamics under varying cellular conditions (sooreshjani2021identifyingtheversatile pages 23-28).
7. Function  
   LIMK2 plays an essential role in the regulation of actin filament dynamics by phosphorylating cofilin, thereby inhibiting its actin-severing activity and promoting the stabilization of filamentous actin. This function is critical for numerous cellular processes including cell migration, adhesion, and morphological changes during differentiation (brion2021limkinasesin pages 2-4, chatterjee2022structuralaspectsof pages 11-12). Beyond its cytoskeletal role, LIMK2 is involved in astral microtubule organization and the proper orientation of the mitotic spindle during early mitosis by phosphorylating target proteins such as TPPP, linking its activity to cell division and genomic stability (brion2021limkinasesin pages 2-4, goyal2005dualfunctionof pages 127-131). Furthermore, LIMK2 suppresses ciliogenesis through multiple mechanisms: by phosphorylating cofilin (CFL1) and thereby modulating actin dynamics, by inhibiting the directional trafficking of ciliary vesicles toward the ciliary base, and by facilitating the nuclear localization of YAP1, where it functions as a transcriptional corepressor of TEAD4 target genes including AURKA and PLK1 (brion2021limkinasesin pages 2-4, jiang2023pdzandlim pages 16-17). LIMK2 is ubiquitously expressed across a range of tissues and is frequently upregulated in various cancers, where its dysregulation contributes to tumor cell motility, invasion, and metastatic progression (villalonga2023limkinaseslimk1 pages 20-21, ohashi2014damnacanthalaneffective pages 12-13).
8. Other Comments  
   A number of small molecule inhibitors targeting LIMK2 have been reported in the literature, offering potential avenues for therapeutic intervention in diseases where LIMK2 is dysregulated. For example, inhibitors such as T56-LIMKi have been developed with reported selectivity toward LIMK2, and bis-aryl urea derivatives have also demonstrated potent inhibitory activity against both LIMK1 and LIMK2 in biochemical assays (yin2015bisarylureaderivatives pages 23-25, ohashi2014damnacanthalaneffective pages 3-4). LIMK2’s involvement in cancer, particularly in promoting tumor cell migration, invasion, and metastasis, has made it a candidate therapeutic target; its regulation by upstream oncogenic kinases such as Aurora A and ROCK further underscores its potential as a drug target (jiang2023pdzandlim pages 16-17, ritchey2014theroleof pages 149-152). In addition, mutations or altered expression levels of LIMK2 can be linked to defects in mitotic spindle orientation and ciliogenesis, suggesting roles in developmental disorders and diseases related to abnormal ciliary function (brion2021limkinasesin pages 2-4, villalonga2023limkinaseslimk1 pages 17-18). Current research continues to explore the specificity and efficacy of LIMK2 inhibitors using both enzymatic assays and cellular models, and the integration of LIMK2 inhibition with other targeted therapies is under investigation in preclinical models of cancer (ohashi2014damnacanthalaneffective pages 12-13, sooreshjani2021identifyingtheversatile pages 93-97).
9. References  
   brion2021limkinasesin pages 1-2; brion2021limkinasesin pages 2-4; chatterjee2022structuralaspectsof pages 1-3; chatterjee2022structuralaspectsof pages 4-6; chatterjee2022structuralaspectsof pages 6-8; chatterjee2022structuralaspectsof pages 10-11; chatterjee2022structuralaspectsof pages 11-12; goyal2005dualfunctionof pages 24-28; goyal2005dualfunctionof pages 109-112; goyal2005dualfunctionof pages 118-121; goyal2005dualfunctionof pages 127-131; goyal2005dualfunctionof pages 30-33; hamill2016structuralbasisfor pages 12-13; jiang2023pdzandlim pages 13-14; jiang2023pdzandlim pages 14-16; jiang2023pdzandlim pages 16-17; johnson2012limk2isa pages 1-2; lateef2024limkinasesin pages 2-4; manetti2012limkinasesare pages 1-3; manetti2012limkinasesare pages 6-9; manetti2012limkinasesare pages 9-11; manetti2012limkinasesare pages 11-14; manetti2012limkinasesare pages 16-18; manetti2012limkinasesare pages 18-21; manetti2012limkinasesare pages 21-23; manetti2012limkinasesare pages 23-25; manetti2012limkinasesare pages 25-27; manetti2012limkinasesare pages 27-29; mashiachfarkash2012computerbasedidentificationof pages 2-4; ohashi2014damnacanthalaneffective pages 1-2; ohashi2014damnacanthalaneffective pages 3-4; ritchey2014theroleof pages 149-152; sooreshjani2021identifyingtheversatile pages 23-28; sooreshjani2021identifyingtheversatile pages 93-97; villalonga2023limkinaseslimk1 pages 1-2; villalonga2023limkinaseslimk1 pages 2-6; villalonga2023limkinaseslimk1 pages 9-10; villalonga2023limkinaseslimk1 pages 10-11; villalonga2023limkinaseslimk1 pages 11-13; villalonga2023limkinaseslimk1 pages 13-15; villalonga2023limkinaseslimk1 pages 17-18; villalonga2023limkinaseslimk1 pages 18-20; villalonga2023limkinaseslimk1 pages 20-21; villalonga2023limkinaseslimk1 pages 21-22.

References

1. (brion2021limkinasesin pages 2-4): Régis Brion, Laura Regnier, Mathilde Mullard, Jérome Amiaud, Françoise Rédini, and Franck Verrecchia. Lim kinases in osteosarcoma development. Cells, 10:3542, Dec 2021. URL: https://doi.org/10.3390/cells10123542, doi:10.3390/cells10123542. This article has 10 citations and is from a peer-reviewed journal.
2. (chatterjee2022structuralaspectsof pages 6-8): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
3. (goyal2005dualfunctionof pages 24-28): P Goyal. Dual function of limk2 in endothelial cells. Unknown journal, 2005.
4. (jiang2023pdzandlim pages 14-16): Xinyuan Jiang, Zhiyong Xu, Sujing Jiang, Huan Wang, Mingshu Xiao, Yuelin Shi, and Kai Wang. Pdz and lim domain-encoding genes: their role in cancer development. Cancers, 15:5042, Oct 2023. URL: https://doi.org/10.3390/cancers15205042, doi:10.3390/cancers15205042. This article has 9 citations and is from a peer-reviewed journal.
5. (jiang2023pdzandlim pages 16-17): Xinyuan Jiang, Zhiyong Xu, Sujing Jiang, Huan Wang, Mingshu Xiao, Yuelin Shi, and Kai Wang. Pdz and lim domain-encoding genes: their role in cancer development. Cancers, 15:5042, Oct 2023. URL: https://doi.org/10.3390/cancers15205042, doi:10.3390/cancers15205042. This article has 9 citations and is from a peer-reviewed journal.
6. (manetti2012limkinasesare pages 21-23): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
7. (mashiachfarkash2012computerbasedidentificationof pages 2-4): Efrat Mashiach-Farkash, Roni Rak, Galit Elad-Sfadia, Roni Haklai, Shmuel Carmeli, Yoel Kloog, and Haim J. Wolfson. Computer-based identification of a novel limk1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget, 3:629-639, Jun 2012. URL: https://doi.org/10.18632/oncotarget.525, doi:10.18632/oncotarget.525. This article has 49 citations and is from a poor quality or predatory journal.
8. (ohashi2014damnacanthalaneffective pages 12-13): Kazumasa Ohashi, Kaori Sampei, Mami Nakagawa, Naoto Uchiumi, Tatsuya Amanuma, Setsuya Aiba, Masato Oikawa, and Kensaku Mizuno. Damnacanthal, an effective inhibitor of lim-kinase, inhibits cell migration and invasion. Molecular Biology of the Cell, 25:828-840, Mar 2014. URL: https://doi.org/10.1091/mbc.e13-09-0540, doi:10.1091/mbc.e13-09-0540. This article has 49 citations and is from a domain leading peer-reviewed journal.
9. (sooreshjani2021identifyingtheversatile pages 23-28): MA Sooreshjani. Identifying the versatile roles of nkx3.1 phosphorylation to explore new castration-resistant prostate cancer therapy. Unknown journal, Apr 2021. URL: https://doi.org/10.25394/pgs.14519691.v1, doi:10.25394/pgs.14519691.v1. This article has 0 citations.
10. (villalonga2023limkinaseslimk1 pages 1-2): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
11. (villalonga2023limkinaseslimk1 pages 10-11): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
12. (villalonga2023limkinaseslimk1 pages 13-15): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
13. (villalonga2023limkinaseslimk1 pages 20-21): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
14. (villalonga2023limkinaseslimk1 pages 9-10): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
15. (yin2015bisarylureaderivatives pages 1-3): Yan Yin, Ke Zheng, Nibal Eid, Shannon Howard, Ji-Hak Jeong, Fei Yi, Jia Guo, Chul Min Park, Mathieu Bibian, Weilin Wu, Pamela Hernandez, HaJeung Park, Yuntao Wu, Jun-Li Luo, Philip V. LoGrasso, and Yangbo Feng. Bis-aryl urea derivatives as potent and selective lim kinase (limk) inhibitors. Journal of medicinal chemistry, 58 4:1846-61, Feb 2015. URL: https://doi.org/10.1021/jm501680m, doi:10.1021/jm501680m. This article has 62 citations and is from a highest quality peer-reviewed journal.
16. (yin2015bisarylureaderivatives pages 23-25): Yan Yin, Ke Zheng, Nibal Eid, Shannon Howard, Ji-Hak Jeong, Fei Yi, Jia Guo, Chul Min Park, Mathieu Bibian, Weilin Wu, Pamela Hernandez, HaJeung Park, Yuntao Wu, Jun-Li Luo, Philip V. LoGrasso, and Yangbo Feng. Bis-aryl urea derivatives as potent and selective lim kinase (limk) inhibitors. Journal of medicinal chemistry, 58 4:1846-61, Feb 2015. URL: https://doi.org/10.1021/jm501680m, doi:10.1021/jm501680m. This article has 62 citations and is from a highest quality peer-reviewed journal.
17. (brion2021limkinasesin pages 1-2): Régis Brion, Laura Regnier, Mathilde Mullard, Jérome Amiaud, Françoise Rédini, and Franck Verrecchia. Lim kinases in osteosarcoma development. Cells, 10:3542, Dec 2021. URL: https://doi.org/10.3390/cells10123542, doi:10.3390/cells10123542. This article has 10 citations and is from a peer-reviewed journal.
18. (chatterjee2022structuralaspectsof pages 1-3): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
19. (chatterjee2022structuralaspectsof pages 10-11): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
20. (chatterjee2022structuralaspectsof pages 11-12): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
21. (chatterjee2022structuralaspectsof pages 4-6): Deep Chatterjee, Franziska Preuss, Verena Dederer, Stefan Knapp, and Sebastian Mathea. Structural aspects of limk regulation and pharmacology. Cells, 11:142, Jan 2022. URL: https://doi.org/10.3390/cells11010142, doi:10.3390/cells11010142. This article has 23 citations and is from a peer-reviewed journal.
22. (goyal2005dualfunctionof pages 109-112): P Goyal. Dual function of limk2 in endothelial cells. Unknown journal, 2005.
23. (goyal2005dualfunctionof pages 118-121): P Goyal. Dual function of limk2 in endothelial cells. Unknown journal, 2005.
24. (goyal2005dualfunctionof pages 127-131): P Goyal. Dual function of limk2 in endothelial cells. Unknown journal, 2005.
25. (goyal2005dualfunctionof pages 30-33): P Goyal. Dual function of limk2 in endothelial cells. Unknown journal, 2005.
26. (hamill2016structuralbasisfor pages 12-13): Stephanie Hamill, Hua Jane Lou, Benjamin E. Turk, and Titus J. Boggon. Structural basis for noncanonical substrate recognition of cofilin/adf proteins by lim kinases. Molecular Cell, 62:397-408, May 2016. URL: https://doi.org/10.1016/j.molcel.2016.04.001, doi:10.1016/j.molcel.2016.04.001. This article has 61 citations and is from a highest quality peer-reviewed journal.
27. (jiang2023pdzandlim pages 13-14): Xinyuan Jiang, Zhiyong Xu, Sujing Jiang, Huan Wang, Mingshu Xiao, Yuelin Shi, and Kai Wang. Pdz and lim domain-encoding genes: their role in cancer development. Cancers, 15:5042, Oct 2023. URL: https://doi.org/10.3390/cancers15205042, doi:10.3390/cancers15205042. This article has 9 citations and is from a peer-reviewed journal.
28. (johnson2012limk2isa pages 1-2): Emmanuel O. Johnson, Kuei-Hua Chang, Soumitra Ghosh, Chelvam Venkatesh, Katie Giger, Philip S. Low, and Kavita Shah. Limk2 is a crucial regulator and effector of aurora-a-kinase-mediated malignancy. Journal of Cell Science, 125:1204-1216, Mar 2012. URL: https://doi.org/10.1242/jcs.092304, doi:10.1242/jcs.092304. This article has 71 citations and is from a domain leading peer-reviewed journal.
29. (lateef2024limkinasesin pages 2-4): Olubodun M. Lateef, Christopher Foote, Gavin Power, Camila Manrique-Acevedo, Jaume Padilla, and Luis A. Martinez-Lemus. Lim kinases in cardiovascular health and disease. Frontiers in Physiology, Dec 2024. URL: https://doi.org/10.3389/fphys.2024.1506356, doi:10.3389/fphys.2024.1506356. This article has 1 citations and is from a peer-reviewed journal.
30. (manetti2012limkinasesare pages 1-3): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
31. (manetti2012limkinasesare pages 11-14): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
32. (manetti2012limkinasesare pages 16-18): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
33. (manetti2012limkinasesare pages 18-21): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
34. (manetti2012limkinasesare pages 23-25): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
35. (manetti2012limkinasesare pages 25-27): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
36. (manetti2012limkinasesare pages 27-29): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
37. (manetti2012limkinasesare pages 6-9): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
38. (manetti2012limkinasesare pages 9-11): Fabrizio Manetti. Lim kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Medicinal Research Reviews, Sep 2012. URL: https://doi.org/10.1002/med.20230, doi:10.1002/med.20230. This article has 145 citations and is from a domain leading peer-reviewed journal.
39. (ohashi2014damnacanthalaneffective pages 1-2): Kazumasa Ohashi, Kaori Sampei, Mami Nakagawa, Naoto Uchiumi, Tatsuya Amanuma, Setsuya Aiba, Masato Oikawa, and Kensaku Mizuno. Damnacanthal, an effective inhibitor of lim-kinase, inhibits cell migration and invasion. Molecular Biology of the Cell, 25:828-840, Mar 2014. URL: https://doi.org/10.1091/mbc.e13-09-0540, doi:10.1091/mbc.e13-09-0540. This article has 49 citations and is from a domain leading peer-reviewed journal.
40. (ohashi2014damnacanthalaneffective pages 3-4): Kazumasa Ohashi, Kaori Sampei, Mami Nakagawa, Naoto Uchiumi, Tatsuya Amanuma, Setsuya Aiba, Masato Oikawa, and Kensaku Mizuno. Damnacanthal, an effective inhibitor of lim-kinase, inhibits cell migration and invasion. Molecular Biology of the Cell, 25:828-840, Mar 2014. URL: https://doi.org/10.1091/mbc.e13-09-0540, doi:10.1091/mbc.e13-09-0540. This article has 49 citations and is from a domain leading peer-reviewed journal.
41. (ritchey2014theroleof pages 149-152): L Ritchey. The role of lim kinase 1 and its substrates in cell cycle progression. Unknown journal, 2014.
42. (sooreshjani2021identifyingtheversatile pages 93-97): MA Sooreshjani. Identifying the versatile roles of nkx3.1 phosphorylation to explore new castration-resistant prostate cancer therapy. Unknown journal, Apr 2021. URL: https://doi.org/10.25394/pgs.14519691.v1, doi:10.25394/pgs.14519691.v1. This article has 0 citations.
43. (villalonga2023limkinaseslimk1 pages 11-13): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
44. (villalonga2023limkinaseslimk1 pages 17-18): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
45. (villalonga2023limkinaseslimk1 pages 18-20): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
46. (villalonga2023limkinaseslimk1 pages 2-6): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.
47. (villalonga2023limkinaseslimk1 pages 21-22): Elodie Villalonga, Christine Mosrin, Thierry Normand, Caroline Girardin, Amandine Serrano, Bojan Žunar, Michel Doudeau, Fabienne Godin, Hélène Bénédetti, and Béatrice Vallée. Lim kinases, limk1 and limk2, are crucial node actors of the cell fate: molecular to pathological features. Cells, 12:805, Mar 2023. URL: https://doi.org/10.3390/cells12050805, doi:10.3390/cells12050805. This article has 34 citations and is from a peer-reviewed journal.